Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ptc Therapeutics (PTCT)

Ptc Therapeutics (PTCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,566,260
  • Shares Outstanding, K 77,125
  • Annual Sales, $ 937,820 K
  • Annual Income, $ -626,600 K
  • EBIT $ 2 M
  • EBITDA $ 456 M
  • 60-Month Beta 0.63
  • Price/Sales 3.72
  • Price/Cash Flow 18.68
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 73.53% ( -3.78%)
  • Historical Volatility 70.84%
  • IV Percentile 64%
  • IV Rank 20.12%
  • IV High 165.94% on 01/24/24
  • IV Low 50.26% on 10/25/24
  • Put/Call Vol Ratio 9.05
  • Today's Volume 9,437
  • Volume Avg (30-Day) 1,247
  • Put/Call OI Ratio 2.57
  • Today's Open Interest 15,826
  • Open Int (30-Day) 7,738

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.33
  • Number of Estimates 5
  • High Estimate -0.66
  • Low Estimate -1.64
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -454.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.21 +12.21%
on 11/21/24
54.16 -14.62%
on 12/03/24
+4.28 (+10.20%)
since 11/20/24
3-Month
34.57 +33.76%
on 10/07/24
54.16 -14.62%
on 12/03/24
+9.60 (+26.20%)
since 09/20/24
52-Week
23.58 +96.10%
on 02/13/24
54.16 -14.62%
on 12/03/24
+19.20 (+71.01%)
since 12/20/23

Most Recent Stories

More News
PTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz Grows

Wells Fargo highlighted the agreement’s $1.9 billion milestone potential, 40% U.S. profit-sharing terms, and double-digit royalties on ex-U.S. sales.

PTCT : 46.24 (+2.19%)
NVS : 97.11 (+0.35%)
PTC Therapeutics: Q3 Earnings Snapshot

PTC Therapeutics: Q3 Earnings Snapshot

PTCT : 46.24 (+2.19%)
3 Top Stocks That Could Still Rocket Higher in 2024

Upcoming Food and Drug Administration decisions could push these stocks through the roof.

PTCT : 46.24 (+2.19%)
VRTX : 397.27 (+0.16%)
BBIO : 26.49 (+1.07%)
RHHBY : 34.5000 (+0.76%)
PFE : 26.36 (+2.29%)
PTC Therapeutics: Q2 Earnings Snapshot

PTC Therapeutics: Q2 Earnings Snapshot

PTCT : 46.24 (+2.19%)
Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024

Stocks that traded heavily or had substantial price changes on Friday: Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise

FCX : 38.86 (+1.62%)
PTCT : 46.24 (+2.19%)
ACCD : 3.48 (+4.82%)
KRUS : 93.62 (-0.11%)
PTGX : 41.49 (+4.93%)
INFN : 6.60 (+0.61%)
PTC Therapeutics: Q1 Earnings Snapshot

PTC Therapeutics: Q1 Earnings Snapshot

PTCT : 46.24 (+2.19%)
PTC Therapeutics: Q4 Earnings Snapshot

PTC Therapeutics: Q4 Earnings Snapshot

PTCT : 46.24 (+2.19%)
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?

Bad news for one player does not always equal good news for another.

SRPT : 118.97 (-0.42%)
PTCT : 46.24 (+2.19%)
PTC Therapeutics: Q3 Earnings Snapshot

PTC Therapeutics: Q3 Earnings Snapshot

PTCT : 46.24 (+2.19%)
Why PTC Therapeutics Soared 15% Higher Today

The company scored a $1 billion upfront payment for expanding a commercial partnership.

PTCT : 46.24 (+2.19%)
RPRX : 24.92 (+2.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.

See More

Key Turning Points

3rd Resistance Point 50.21
2nd Resistance Point 48.81
1st Resistance Point 47.53
Last Price 46.24
1st Support Level 44.85
2nd Support Level 43.45
3rd Support Level 42.17

See More

52-Week High 54.16
Last Price 46.24
Fibonacci 61.8% 42.48
Fibonacci 50% 38.87
Fibonacci 38.2% 35.26
52-Week Low 23.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar